LIVE
EXAS
Exact Sciences Corporation · Health Care - Diagnostics
N/A
N/A this month
VERSUS
⟷
COMPARE
GDRX
GoodRx Holdings, Inc. · Health Care - Healthcare Technology
$2.66
+5.56% this month
Scoreboard verdict
Across AI score, momentum, valuation, upside, operating margin
EXAS
0
GDRX
0
Comparison scoreboard
MIXED SETUPAI Score
EXAS N/A
GDRX 22.4
1Y Return
EXAS N/A
GDRX -40.62%
Fwd P/E
EXAS N/A
GDRX 7.43
Target Up.
EXAS N/A
GDRX +19.58%
Op. Margin
EXAS N/A
GDRX N/A
Metrics last refreshed: 6/20/2026
Quick take
EXAS vs GDRX Stock Comparison: AI Score, Valuation, Performance and Upside
EXAS provides cancer screening and diagnostic tests with a growing commercial infrastructure, while GDRX offers a prescription drug price transparency platform with an asset-light business model. Both are healthcare technology companies but serving very different parts of the patient journey.
EXAS vs GDRX compares two health technology companies at different points of their growth trajectories — Exact Sciences' diagnostics-driven cancer screening franchise versus GoodRx's consumer prescription price platform navigating PBM headwinds.
Live analysis · updated 6/20/2026
EXAS and GDRX are closely matched — they split the tracked metrics evenly.
Normalized 1Y performance
EXAS
GDRX
Not enough data to chart yet.
Recent returns
EXAS
GDRX
Analyst price targets & sentiment
EXAS
Price target data unavailable
N/A
GDRX · 13 analysts
STRONG BUYHOLDSTRONG SELL
Hold (2.5/5.0)
Price target range
analyst low$2.25
analyst high$4.00
analyst mean$3.18
current price$2.66
+19.6% upside to analyst mean
Who should consider this stock?
EXAS may suit investors who:
- →Want exposure to the leading non-invasive colorectal cancer screening platform
- →Believe Cologuard and next-generation cancer screening tests will continue taking market share
- →See the large unscreened colorectal cancer patient population as a long-term growth opportunity
GDRX may suit investors who:
- →Want exposure to a consumer healthcare price transparency platform with broad brand recognition
- →See value in GoodRx's expansion into telehealth and pharmaceutical manufacturer programs
- →Believe GoodRx's core economics will stabilize after recent PBM headwinds
Performance & AI score
| Metric | EXAS | GDRX |
|---|---|---|
| AI score | N/A | 22.4 |
| AI rank | N/A | #4137 |
| Latest close | N/A | $2.66 |
| 1M return | N/A | +5.56% |
| 6M return | N/A | -4.32% |
| 1Y return | N/A | -40.62% |
$10,000 invested — hypothetical growth (dividends reinvested)
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | EXAS | GDRX |
|---|---|---|
| 1Y ago | N/A | $5.94K (-40.6%) started 2025-06-18 |
| 5Y ago | N/A | $706.88 (-92.9%) started 2021-06-18 |
| 10Y ago | N/A | $526.73 (-94.7%) started 2020-09-23 |
Hypothetical — past performance does not guarantee future results.
Valuation & upside potential
| Metric | EXAS | GDRX |
|---|---|---|
| Market cap | N/A | $900.88M |
| Trailing P/E | N/A | 44.33 |
| Forward P/E | N/A | 7.43 |
| Price/Sales | 6.17 | 1.14 |
| EV/Revenue | N/A | 1.56 |
| Analyst target | N/A | $3.18 |
| Target upside | N/A | +19.58% |
Growth, profitability & risk
| Metric | EXAS | GDRX |
|---|---|---|
| Revenue growth | N/A | -4.40% |
| Earnings growth | N/A | -88.30% |
| EPS growth | N/A | -88.30% |
| FCF margin | N/A | +10.74% |
| Operating margin | N/A | N/A |
| Profit margin | N/A | 2.61% |
| ROIC proxy | N/A | 3.22% |
| Return on equity | N/A | 3.22% |
| Dividend yield | N/A | 0.00% |
| Beta | -0.16 | 1.61 |
| Debt/equity | N/A | 87.04 |
| Current ratio | N/A | 1.47 |
| Quick ratio | N/A | 0.56 |
Drawdown & downside risk
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
1Y risk snapshot
EXAS max drawdownN/A
GDRX max drawdown63.48%
EXAS max wkly dropN/A
GDRX max wkly drop27.56%
5Y risk snapshot
EXAS max drawdownN/A
GDRX max drawdown96.03%
EXAS max wkly dropN/A
GDRX max wkly drop47.48%
10Y risk snapshot
EXAS max drawdownN/A
GDRX max drawdown96.73%
EXAS max wkly dropN/A
GDRX max wkly drop47.48%
Performance metrics by period
| Period | Metric | EXAS | GDRX |
|---|---|---|---|
| 1Y | Growth | N/A | -40.62% |
| CAGR | N/A | -40.65% | |
| Sharpe ratio | N/A | -0.42 | |
| Max drawdown | N/A | 63.48% | |
| Max daily drop | N/A | 20.05% | |
| Max wkly drop | N/A | 27.56% | |
| 5Y | Growth | N/A | -92.93% |
| CAGR | N/A | -41.14% | |
| Sharpe ratio | N/A | -0.42 | |
| Max drawdown | N/A | 96.03% | |
| Max daily drop | N/A | 38.91% | |
| Max wkly drop | N/A | 47.48% | |
| 10Y | Growth | N/A | -94.73% |
| CAGR | N/A | -40.16% | |
| Sharpe ratio | N/A | -0.41 | |
| Max drawdown | N/A | 96.73% | |
| Max daily drop | N/A | 38.91% | |
| Max wkly drop | N/A | 47.48% |
Business comparison
| Category | EXAS | GDRX |
|---|---|---|
| Company | Exact Sciences Corporation | GoodRx Holdings, Inc. |
| Sector | Health Care - Diagnostics | Health Care - Healthcare Technology |
| Industry | N/A | N/A |
| Core business | Exact Sciences provides non-invasive cancer screening and diagnostic tests, led by Cologuard (colorectal cancer screening stool DNA test) and Oncotype DX (tumor profiling tests for breast, colon, and prostate cancer treatment decisions). | GoodRx provides a consumer-facing digital platform for comparing and accessing discounted prescription drug prices across U.S. pharmacies, allowing uninsured and underinsured patients to pay less than list price for their medications. |
| Investor focus | Investors track Cologuard's customer growth and revenue, anticipated next-generation Cologuard screening test launch, and Oncotype DX precision oncology testing volume. | Investors track GoodRx's monthly active consumer growth, prescription revenue (from pharmacy PBM spread), and expansion into newer healthcare services including telehealth and pharmaceutical manufacturer programs. |
EXAS strengths
- →Cologuard is the leading non-invasive colorectal cancer screening test with Medicare coverage and broad physician adoption
- →Oncotype DX provides genomic test results that guide chemotherapy decisions in breast cancer
- →Large addressable market as colorectal cancer screening compliance remains below clinical guidelines
GDRX strengths
- →Leading consumer brand for prescription drug price comparison in the U.S.
- →Asset-light business model connecting consumers, pharmacies, and pharmacy benefit managers
- →Expanding beyond prescription discounts into telehealth and manufacturer direct-to-patient programs
Risks to watch — EXAS
- →Cologuard faces competition from Guardant Health's Shield blood-based colorectal cancer screening test
- →High operating expenses relative to revenue have kept Exact Sciences unprofitable despite strong Cologuard revenue growth
- →Next-generation Cologuard must maintain superiority as competing approaches improve
Risks to watch — GDRX
- →Core prescription discount business has faced revenue headwinds from PBM (pharmacy benefit manager) changes affecting discount spread economics
- →Growth has moderated significantly from COVID-era highs
- →Competition from Amazon Pharmacy, Blink Health, and other prescription discount platforms
Frequently asked questions
Free public comparison
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Related comparisons
More comparisons
Browse all 1,000 comparisons →